# An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

> **NCT03934086** · — · NO_LONGER_AVAILABLE · sponsor: **Pfizer**

## Conditions studied

- Migraine

## Interventions

- **DRUG:** rimegepant

## Key facts

- **NCT ID:** NCT03934086
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03934086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03934086, "An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03934086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*